Dual Improvement of Alopecia Areata and Immune Thrombocytopenia With Baricitinib: A Case Report

    January 2025 in “ Skin Health and Disease ”
    Chelsea Moon, Sarah Park, Jennifer L. Hsiao, Katrina Lee
    Studysummary In this report, oral baricitinib improved both alopecia areata and immune thrombocytopenia in a 56-year-old patient, suggesting a potential dual benefit for these conditions, although regular platelet monitoring and hematology consultation are recommended.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on academic.oup.com →
    Discuss this study in the Community →

    Research cited in this study 6

    1. A Case of Alopecia Areata Multiplex Accompanied by Chronic Idiopathic Thrombocytopenic Purpura The Journal of Dermatology · 2024
    2. Inhibition of T-Cell Activity in Alopecia Areata: Recent Developments and New Directions Frontiers in immunology · 2023
    3. Two Phase 3 Trials of Baricitinib for Alopecia Areata The New England Journal of Medicine · 2022
    4. Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib EBioMedicine · 2015
    5. Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition Nature medicine · 2014
    6. Simultaneous Onset of Alopecia Areata and Idiopathic Thrombocytopenic Purpura: A Potential Association? Pediatric Dermatology · 1999

    Related research 1

    1. Twenty Nail Dystrophy with Alopecia Areata in an Atopic Child International journal of research in dermatology · 2019